SV Health Investors Completes Acquisition of EpiVax
SV Health Investors has announced the acquisition of EpiVax, Inc., a well-established contract research organization (CRO) specializing in immunogenicity risk assessment for pharmaceutical and biotechnology companies. The transaction marks a new platform investment for SV Health Investors and underscores its continued focus on building and scaling healthcare and life sciences service providers.
Headquartered in Providence, Rhode Island, EpiVax has built a strong reputation over more than 25 years as a pioneer in preclinical drug development, particularly in the field of immunogenicity. The company provides advanced analytical and predictive tools that help pharmaceutical and biotech clients assess the potential immune response risks associated with therapeutic candidates. These services are critical in modern drug development, as immunogenicity can significantly impact both the safety and efficacy of biologic therapies.
EpiVax’s expertise has made it a trusted scientific advisor to a wide range of life sciences organizations, supporting decision-making at early stages of development and helping to guide programs toward regulatory readiness. Its long-standing relationships with clients and its emphasis on scientific rigor have positioned the company as a leader in a highly specialized and increasingly important segment of the CRO market.
The acquisition aligns closely with SV Health Investors’ broader investment strategy, which focuses on partnering with founders and management teams to build high-quality healthcare businesses. By bringing EpiVax into its portfolio, SV Health Investors aims to leverage its experience and resources to accelerate the company’s growth while maintaining its strong scientific foundation and customer-centric culture.
Annie De Groot, MD, founder of EpiVax, highlighted the significance of the partnership as a transformative step for the company. She emphasized that the investment reflects confidence in EpiVax’s leadership, capabilities, and long-standing commitment to innovation in immunogenicity research. According to De Groot, the collaboration with SV Health Investors provides an opportunity to expand the company’s impact while preserving the core values that have defined its success.
SV Health Investors brings extensive expertise in tech-enabled pharmaceutical services, supported by a broad network across the biotechnology and pharmaceutical industries. Over the years, the firm has made several notable investments in the sector, including companies such as Adimab, Clario (formerly BioClinica), Celerion, and Leiters. These investments highlight SV Health Investors’ track record of supporting organizations that provide critical services to the life sciences ecosystem.
A.J. Rossi, Partner at SV Health Investors, noted that EpiVax has demonstrated strong and consistent growth, driven by its differentiated capabilities and deep scientific expertise. He подчеркнул that the firm intends to support the company through strategic guidance, capital investment, and access to its extensive industry network. At the same time, SV Health Investors aims to preserve EpiVax’s unique culture and its focus on delivering high-quality service to clients.
From EpiVax’s perspective, the partnership is expected to enhance its ability to scale operations and expand its service offerings. Rich-Henry Schabowsky, PhD, JD, Chief Executive Officer of EpiVax, stated that the collaboration will strengthen the company’s leadership position in immunogenicity risk assessment while accelerating innovation. He highlighted that access to additional resources and expertise will enable EpiVax to better support global pharmaceutical and biotechnology partners in managing risk, optimizing development pathways, and achieving regulatory compliance more efficiently.
As part of its growth strategy, EpiVax plans to expand its capabilities in several key areas. These include the development of advanced computational tools designed to improve predictive modeling of immune responses, as well as the expansion of cell-based assay applications that can provide more detailed insights into biological mechanisms. Additionally, the company intends to broaden its analytical consulting services, offering clients more comprehensive support across the drug development lifecycle.
These planned enhancements reflect broader trends in the pharmaceutical industry, where there is increasing demand for sophisticated analytical solutions that can address complex scientific challenges. As biologic therapies and novel modalities continue to grow in prominence, the ability to accurately assess immunogenicity risk has become a critical component of successful drug development. Companies like EpiVax play a vital role in enabling this process by providing specialized expertise and tools that help reduce uncertainty and improve outcomes.
The transaction also highlights the growing importance of outsourced services in the life sciences sector. Pharmaceutical and biotechnology companies are increasingly relying on external partners to access specialized capabilities, improve efficiency, and accelerate timelines. CROs that offer high-value, science-driven services are particularly well-positioned to benefit from this trend, making them attractive investment opportunities for firms like SV Health Investors.
In connection with the acquisition, legal advisory roles were provided by Morgan Lewis & Bockius LLP for SV Health Investors and Foley & Lardner LLP for EpiVax. Their involvement underscores the complexity and strategic importance of the transaction.
Overall, the acquisition of EpiVax by SV Health Investors represents a significant milestone for both organizations. For EpiVax, it provides the resources and strategic support needed to expand its capabilities and extend its leadership in immunogenicity risk assessment. For SV Health Investors, it adds a high-quality platform company to its portfolio, further strengthening its presence in the outsourced pharmaceutical services market.
As the partnership moves forward, both companies are expected to focus on driving innovation, expanding global reach, and delivering enhanced value to clients across the life sciences industry. The combination of EpiVax’s scientific expertise and SV Health Investors’ strategic and financial support positions the business for continued growth in an increasingly complex and competitive landscape.
About EpiVax
Founded in 1998, EpiVax is a leading bioanalytical CRO specializing in immunogenicity risk assessment for the pharmaceutical and biotechnology industries. EpiVax’s predictive analytical software platform (“ISPRI”) and in vitro laboratory services enable life sciences companies to identify safety and efficacy risks early in drug development, reducing timelines and R&D costs. EpiVax is a scientific thought leader, validated through over 230 peer-reviewed publications, delivering actionable insights via proprietary computational tools and laboratory services. Visit www.epivax.com to learn more.
About SV Health Investors
SV Health Investors (“SVHI”) is a private investment firm dedicated to investments in the healthcare and life sciences sector. Founded in 1993 with offices in Boston and London, SVHI manages over $2.0B across multiple investment strategies. SVHI’s dedicated healthcare Growth-Buyout strategy partners with experienced management teams to accelerate the success of innovative healthcare companies across pharma services, medical technology, and tech-enabled healthcare services. SVHI combines decades of healthcare transaction and operating experience to drive long-term value creation and realize the triple aim of healthcare – higher quality care, accessible to more patients, at a lower cost.
Source Link:https://www.businesswire.com/
